COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE

被引：1
|
作者：
Solakidi, A. [1 ]
Tzanetakos, C. [1 ]
Kontodimas, S. [2 ]
Kourlaba, G. [1 ]
机构：
[1] EVROSTON LP, Athens, Greece
[2] LEO Pharma Hellas, Athens, Greece
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2532
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS32
引用
收藏
页码：S428 / S428
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Gourzoulidis, G.
    Rigopoulos, D.
    Kountouris, V
    Christou, P.
    Kiri, S.
    Tzanetakos, C.
    [J]. VALUE IN HEALTH, 2019, 22 : S422 - S422
  • [2] COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A803 - A803
  • [3] COST-EFFECTIVENESS OF SECUKINUMAB COMPARED WITH USTEKINUMAB AND ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Tzanetakos, C.
    Kourlaba, G.
    Chatzikou, M.
    Antoniou, C.
    Ioannidis, D.
    Lefaki, I
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, A.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [4] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
  • [5] COST-EFFECTIVENESS ANALYSIS OF BIMEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Koulentaki, M.
    Tzanetakos, C.
    Stratigos, A.
    Sotiriou, E.
    Ladha, I
    Christou, P.
    Relakis, J.
    Kourlaba, G.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S74 - S74
  • [6] Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
    Hendrix, Nathaniel
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Loos, Anne
    Liu, Shanshan
    Kumar, Varun
    Linder, Jeffrey A.
    Pearson, Steven D.
    Veenstra, David L.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (12): : 1210 - +
  • [7] Cost-effectiveness of treatment for moderate-to-severe psoriasis
    Hankin, CS
    Feldman, SR
    Pearce, D
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 654 - 654
  • [8] MODELING THE COST-EFFECTIVENESS OF USTEKINUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN US
    Verma, S.
    Dharmarajan, S.
    Yang, Y.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
  • [9] COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS
    Ortonne, J. P.
    Feneron, D.
    Daures, J. P.
    Ollivier, A. L.
    Thiriet, C.
    Maurel, F.
    Le Pen, C.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A617 - A617
  • [10] Brodalumab: A Review in Moderate to Severe Plaque Psoriasis
    Hannah A. Blair
    [J]. Drugs, 2018, 78 : 495 - 504
12345